Loading
A phase 2 trial of Romidepsin in Alveolar soft part sarcoma, Angiosarcoma, Epithelioid sarcoma, Chondrosarcoma, Osteosarcoma and Leiomyosarcoma, run by National Cancer Institute (NCI), completed.
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma is a phase 2 interventional study registered as NCT00112463 by National Cancer Institute (NCI), with 40 participants recorded, started 2005-01-07 and reaching its primary completion in 2008-10-23. Interventions recorded: romidepsin. Conditions recorded: Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma, Adult Malignant Hemangiopericytoma, Adult Malignant Mesenchymoma, Adult Neurofibrosarcoma, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Gastrointestinal Stromal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Adult Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma.
Linked to the drug Romidepsin because the registry names it among its interventions and Alveolar soft part sarcoma, Angiosarcoma, Epithelioid sarcoma, Chondrosarcoma, Osteosarcoma and Leiomyosarcoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Romidepsin and the tag pipeline.
Shares Epithelioid sarcoma and the tag pipeline.
Shares Angiosarcoma and the tag pipeline.
Shares Epithelioid sarcoma and the tag pipeline.
Shares Romidepsin and the tag pipeline.
Shares Alveolar soft part sarcoma and the tag pipeline.
Shares Leiomyosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.